News Release

August 26, 2020
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Personnel Changes

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that personnel changes effective from September 1, 2020 as follows.

JCR will create a post in charge of the vaccine business within the Corporate Planning Division, in order to conduct a wide range of cross-sectional and urgent response measures in the production of a drug substance in Japan for a COVID-19 vaccine currently under development by AstraZeneca K.K. In addition, JCR will create the post of Senior Director of the Sales Division, in order to strengthen the back-office organization of the Sales Division. The Senior Director will be responsible mainly for the Sales Operations Dept. and the Marketing Dept., while supporting the Executive Director of the Sales Division.

Personnel Changes

Name	New Title	Current Title
Yoshio Hiyama, Ph.D.	Director, Corporate Planning Division (Vaccine Business) Director, Pharmacovigilance Dept*.	Director, Pharmacovigilance Dept. Manager, PMS Office
Hironori Yamaguchi	Senior Director, Sales Division	-
Mariko Okada	Director, Pharmacovigilance Dept.	Associate Principal, Safety Information Office, Pharmacovigilance Dept.

*Yoshio Hiyama will support Mariko Okada, who is the new director of Pharmacovigilance Dept.

[About JCR Pharmaceuticals]

JCR is a specialty pharma company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, "Contributing towards people's healthcare through pharmaceutical products" drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations.

[Cautionary Statement Regarding Forward-Looking Statements]

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such

as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights , an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jcrpharm.co.jp

END

###